4D Molecular Therapeutics, Inc.
NASDAQ:FDMTBiotechnology
+$0.16 today
- Market cap
- $577.85M
- Beta
- 2.76
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$2.36
Volume 0.68M
Average 0.77M
FDMT Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
4D Molecular Therapeutics, Inc.NASDAQ: FDMT
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows in line with its trailing trend
Q1 FY2026 depreciation & amortization of $2.06M rose 17.2% year over year, ahead of the +15.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 3.8% from the prior quarter. Over 3 fiscal years it compounded at +25.3% a year.
Context
- Depreciation & amortization amounted to 8.9% of revenue in FY2025, down 18112.7 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +17.2% holds above the trailing-twelve-month pace of +15.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 7.63M USD
- Year-over-year change
- +13.7%
- 4-year CAGR
- +26.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.63M | +13.7% |
| FY2024 | 2024-12-31 | 6.71M | +16.6% |
| FY2023 | 2023-12-31 | 5.75M | +48.2% |
| FY2022 | 2022-12-31 | 3.88M | +28.5% |
| FY2021 | 2021-12-31 | 3.02M | — |
Depreciation & Amortization vs competitors
How FDMT compares with its peers on the latest reported figures
- FDMT's LTM Mar 2026 depreciation & amortization of $7.93M is the 3rd largest of the 8 companies compared; the peer median is $3.62M.
- Its year-over-year change of +15.5% is the 3rd highest of 8, against a peer median of -3.0%.
- Depreciation & amortization amounts to 9.0% of revenue for FDMT, versus a peer median of 32.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $28.32M | +126.8% | +13.8% | 35.5% | |
| LTM Mar 2026 | $15.52M | -3.0% | +6.5% | 17.7% | |
| LTM Mar 2026 | $7.93M | +15.5% | +25.3% | 9.0% | |
| LTM Mar 2026 | $5.93M | -59.2% | +20.0% | 32.8% | |
| LTM Mar 2026 | $3.62M | +20.6% | -8.0% | 24.9% | |
| LTM Mar 2026 | $2.18M | -186.0% | — | — | |
| LTM Mar 2026 | $2.07M | -23.3% | +70.7% | 46.4% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1.99M | -1.7% | -30.8% | — |
| Peer median (excluding FDMT) | $3.62M | -3.0% | +10.2% | 32.8% | |
Competitors are the stored peer set for FDMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.32M) | (107.49M) | (100.84M) | (160.87M) | (140.11M) |
| Depreciation & Amortization | 3.02M | 3.88M | 5.75M | 6.71M | 7.63M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 13.8M | 17.12M | 19.67M | 26.12M | 22.02M |
| Change in Working Capital | (15.53M) | (1.34M) | 630K | 537K | 6.17M |
| Accounts Receivables | 1.44M | 47K | 0 | 0 | 0 |
| Inventory | (4.54M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.29M | (1.64M) | 896K | 871K | 6.77M |
| Other Working Capital | (14.72M) | 255K | (266K) | (334K) | (601K) |
| Other Non-Cash Items | 898K | 1.14M | (999K) | (7.08M) | (4.79M) |
| Operating Cash Flow | (69.13M) | (86.69M) | (75.79M) | (134.59M) | (109.08M) |
| Capital Expenditures | (9.11M) | (11.54M) | (2.77M) | (3.79M) | (536K) |
| Acquisitions (Net) | 9.11M | 0 | 0 | 0 | 0 |
| Purchases of Investments | (168.57M) | (153.31M) | (54.8M) | (467.65M) | (442.82M) |
| Sales of Investments | 5M | 147.8M | 173.29M | 169M | 350.38M |
| Other Investing Activities | (9.11M) | 0 | 173.29M | 0 | 0 |
| Investing Cash Flow | (172.68M) | (17.05M) | 115.72M | (302.44M) | (92.97M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 114.3M | 3.09M | 148.34M | 331.41M | 112.96M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.79M | 0 | 8.49M | 5.84M | 0 |
| Financing Cash Flow | 118.09M | 3.09M | 156.83M | 337.25M | 112.96M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (123.73M) | (100.65M) | 196.76M | (99.77M) | (89.1M) |
| Free Cash Flow | (78.24M) | (98.22M) | (78.56M) | (138.37M) | (109.08M) |
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
Intrinsic Alpha fair value
Locked
Current Price
$10.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.